EMA Consults On Managing Serious Breaches Under EU Clinical Trials Regulation
The European Medicines Agency has issued a draft guideline that explains how drug sponsors should report serious breaches under the upcoming EU Clinical Trials Regulation. The guideline contains a non-exhaustive list of what may or may not qualify as a serious breach.
You may also be interested in...
The number of deficiencies found by EU GCP inspectors rose to 1,033 in 2016, compared with 912 in 2015, although the number of problematic findings considered “critical” was down slightly. Meanwhile, Japan has asked to join the EMA/FDA initiative on GCP inspections.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.